Glycoprotein gp as a basis for the universal vaccine against Ebola virus disease

Dolzhikova Iv; Tukhvatulin Ai; Gromova As; Grousova Dm; Tukhvatulina Nm; Tokarskaya Ea; Logunov Dy; Naroditskiy Bs; Gintsburg Al

GLYCOPROTEIN GP AS A BASIS FOR THE UNIVERSAL VACCINE AGAINST EBOLA VIRUS DISEASE

Dolzhikova IV Tukhvatulin AI, Gromova AS, Grousova DM, Tukhvatulina NM, Tokarskaya EA, Logunov DY, Naroditskiy BS, Gintsburg AL

N.F. Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia

Ebola virus disease (EVD) is one of the deadliest viral infections affecting humans and nonhuman primates. Of 6 known representatives of the Ebolavirus genus responsible for the disease, 3 can infect humans, causing acute highly contagious fever characterized by up to 90% fatality. These include Bundibugyo ebolavirus (BDBV), Zaire ebolavirus (ZEBOV) and Sudan ebolavirus (SUDV). The majority of the reported EVD cases are caused by ZEBOV. Vaccine development against the virus started in 1976, immediately after the causative agent of the infection was identified. So far, 4 vaccines have been approved. All of them are based on the protective epitope of the ZEBOV glycoprotein GP. Because SUDV and BDBV can also cause outbreaks and epidemics, it is vital to design a vaccine capable of conferring protection against all known ebolaviruses posing a threat to the human population. This article presents systematized data on the structure, immunogenicity and protective properties of ebolavirus glycoprotein GP, looks closely at the immunodominant epitopes of ZEBOV SUDV and BDBV glycoprotein GP required to elicit a protective immune response, and offers a rational perspective on the development of a universal vaccine against EVD that relies on the use of vectors expressing two variants of GP represented by ZEBOV and SUDV

Keywords: Ebola virus disease, EVD, vaccines, cross-reactive immunity, cross-protective immunity

Author contribution: Dolzhikova IV, Tukhvatulin AI and Logunov DY conceived and planned the study, analyzed the literature, collected, analyzed and interpreted the data; Gromova AS, Grousova DM, Tukhvatulina NM, and Tokarskaya EA helped to collect and analyze the data; Naroditskiy BS and Gintsburg AL contributed to data interpretation; Dolzhikova IV wrote this manuscript.

^ Correspondence should be addressed: Inna V Dolzhikova Gamalei 18, Moscow, 123098; i.dolzhikova@gmail.com

Received: 06.12.2018 Accepted: 20.02.2019 Published online: 03.03.2019

DOI: 10.24075/brsmu.2019.005

ИСПОЛЬЗОВАНИЕ ГЛИКОПРОТЕИНА GP ДЛЯ СОЗДАНИЯ УНИВЕРСАЛЬНОЙ ВАКЦИНЫ ПРОТИВ ЛИХОРАДКИ ЭБОЛА

И. В. Должикова А. И. Тухватулин, А. С. Громова, Д. М. Гроусова, Н. М. Тухватулина, Е. А. Токарская, Д. Ю. Логунов, Б. С. Народицкий, А. Л.Гинцбург

Национальный исследовательский центр эпидемиологии и микробиологии имени Н. Ф. Гамалеи, Москва, Россия

Болезнь, вызванная вирусом Эбола (БВВЭ) — одно из самых высоколетальных вирусных заболеваний, поражающих человека и приматов. Возбудителем БВВЭ является вирус Эбола. В настоящее время известно шесть видов этого вируса, три из них патогенны для человека — это виды Заир (ZEBOV), Судан (SUDV) и Бундибугио (BDBV), вызывающие острые вирусные высоконтагиозные лихорадки у людей и приматов с летальностью до 90%. В большинстве случаев БВВЭ вызвана видом ZEBOV. Разработка вакцин против БВВЭ началась сразу после идентификации возбудителя в 1976 г. На сегодняшний день в мире зарегистрировано четыре вакцинных препарата для профилактики БВВЭ. Все они основаны на протективном антигене — гликопротеине (GP) вируса Эбола вида ZEBOV В силу того что виды SUDV и BDBV также могут быть причиной вспышек и эпидемий БВВЭ, очевидна необходимость разработки вакцин, способных обеспечить защиту от всех известных патогенных для человека видов вируса Эбола. В статье систематизированы данные относительно структуры, иммуногенных и протективных свойств GP вируса Эбола, проведен анализ иммунодоминантных эпитопов гликопротеина вирусов ZEBOV, SUDV и BDBV необходимых для формирования протективного иммунитета, а также предложен рациональный, на наш взгляд, подход создания возможных вариантов вакцин против БВВЭ, вызванной разными видами вируса Эбола, состоящий в использовании векторных конструкций, экспрессирующих как минимум два варианта гликопротеина — GP вируса Эбола вида ZEBOV и вида SUDV.

Ключевые слова: болезнь, вызванная вирусом Эбола; БВВЭ; вакцины; кросс-реактивный иммунитет; кросс-протективный иммунитет

Информация о вкладе авторов: И. В. Должикова — анализ литературы, планирование исследования, сбор, анализ и интерпретация данных, подготовка рукописи; А. И. Тухватулин — анализ литературы, планирование исследования, сбор, анализ, интерпретация данных; А. С. Громова, Д. М. Гроусова, Н. М. Тухватулина, Е. А. Токарская — сбор и анализ данных; Д. Ю. Логунов — анализ литературы, планирование исследования, анализ и интерпретация данных; Б. С. Народицкий — интерпретация данных; А. Л. Гинцбург — интерпретация данных.

Для корреспонденции: Инна Вадимовна Должикова ул. Гамалеи, д. 18, г. Москва, 123098; i.dolzhikova@gmail.com

Статья получена: 06.12.2018 Статья принята к печати: 20.02.2019 Опубликована онлайн: 03.03.2019 DOI: 10.24075/vrgmu.2019.005

Ebola virus disease (EVD) is one of the most dangerous viral infections afflicting humans and nonhuman primates. Its first reported outbreak occurred in 1976 in Yambuku, a village in the Democratic Republic of the Congo (former Zaire), and Nzara, a town in South Sudan. That same year, the causative agent of the disease — Ebolavirus, a member of the Filoviridae family — was first isolated from an infected individual who lived in the Ebola river valley that gave its name to the virus [1]. So far, 6 ebolaviruses are known including Bundibugyo ebolavirus (BDBV), Zaire ebolavirus (ZEBOV), Reston ebolavirus (RESTV), Sudan ebolavirus (SUDV), Tai forest ebolavirus (TAFV), and Bombali ebolavirus (BOMV). ZEBOV, SUDV and BDBV are capable of infecting humans and therefore pose a serious threat [2-3]. Since 1976, the world has seen more than 20 outbreaks

of EVD caused by ZEBOV, SUDV and BDBV. The largest outbreak that occurred in 2014-2016 in West Africa grew into an epidemic and killed over 12,000 people. The majority of all reported EVD cases have been attributed to ZEBOV (Table 1) [4].

ZEBOV, SUDV and BDBV cause acute, highly contagious fever in humans and nonhuman primates. RESTV is not known to cause EVD in humans; however, antibodies against this species are detected in the blood serum of individuals who work with monkeys and apes infected with RESTV [4]. The reasons behind such different pathogenicity of RESTV and other pathogenic types of Ebola virus are still unknown.

The epidemic of 2014-2016 urged the researchers all around the globe to put increasing effort into developing a vaccine against EVD. To date, over 10 vaccines have been developed,

of which 4 have already been approved for clinical use [5]. Both candidate and approved vaccines confer 100% protection against ZEBOV-associated EBV in nonhuman primates. Their efficacy against other ebolaviruses varies. Because SUDV and BDBV can also cause outbreaks and epidemics and because new ZEBOV strains are emerging, the world is faced with a pressing need for vaccine capable of protecting the human population against all known pathogenic ebolaviruses.

The structure of the virus

Ebolaviruses have a filamentous structure that comes in different shapes and length. The virions consist of an envelope, a nucleocapsid, a polymerase complex and a matrix [6] (Fig. 1). The nucleocapsid core of the virion contains a replication complex composed of a single-stranded RNA genome and a few proteins, including NP, VP35, VP30, and polymerase L. The virus has an outer lipid membrane with glycoprotein (GP) spikes on its surface. The protein matrix formed by proteins VP40 and VP24 lies immediately beneath the outer membrane [6].

The viral genome is represented by negative single-stranded RNA (Fig. 2) [6] carrying 7 genes that code for a total of 9 proteins: the nucleoprotein (NP), the viral polymerase cofactor VP35, the major matrix protein VP40, 3 glycoproteins (the secreted sGP, the full-length GP and the small secreted ssGP), the minor nucleoprotein VP30, the membrane-associated protein VP24, and the viral polymerase L [6-7].

The GP glycoprotein of the Ebolavirus is the only protein located on the surface of the virion. It plays a key role in the early stages of infection helping the virion to attach to and enter the cell [7].

Synthesis and proteolytic processing of GP

The ebolavirus glycoprotein gene codes for 3 proteins: pre-sGP, pre-ssGP (they both are precursors of secreted nonstructural glycoproteins) and pre-GP (a precursor of the structural transmembrane glycoprotein). The nucleotide sequence of the glycoprotein gene contains 7 consecutive uracils at positions 880-886, where a hairpin loop is formed. It is difficult for the viral L polymerase to read through the hairpin [7-8]; therefore, this RNA region undergoes editing. As a result, 3 transcripts are produced:

- a transcript containing 7 uracils (~71%), coding for sGP (364 aa);

- a transcript containing 8 uracils (~25%), coding for GP (676 aa);

- a transcript containing 9 uracils (~4%), coding for ssGP (298 aa).

The first 295 amino acids bases in GP, sGP and ssGP are identical; however, the proteins differ in their C-terminus, which naturally affects their function. A newly synthesized pre-sGP is processed by cell proteases, leading to the formation of secreted sGP, that reduces the efficacy of humoral response

by misdirecting antibodies and A-peptide responsible for pore formation in the cell membrane (Fig. 2) [8-9].

Pre-GP is also cleaved by cell proteases into two subunits: GP1 and GP2. The subunits form heterodimers that are trimerized and constitute spikes on the surface of the viral particle. GP1 contains a receptor-binding domain, a glycan cap and a mucin-like domain required for the interaction with cell surface receptors. GP2 is a transmembrane domain, anchoring the complex in the membrane (Fig. 2). GP2 has a binding site for the TACE protease; in proteolytic cleavage, the glycoprotein is cut off from the membrane and another type of GP is formed: the shed GP [8].

Mature surface GP exerts one of the most crucial functions in the lifecycle of the virus: it interacts with cell receptors, promoting fusion of the virion with the membrane. The virus is taken up into the endocytic/macropinocytic pathway; then, the mucin-like domain and the glycan cap of the glycoprotein are cut off by furin and cathepsins in the cell endosome. The truncated GP binds to Niemann-Pick C1 (NCP1) cholesterol transporter, initiating fusion of the endosomal and viral membranes and allowing the nucleocapsid to enter the cytoplasm [10-11].

Structural and immunogenic features of different GP forms

All secretory forms of GP (sGP, ssGP and shed GP) serve to protect the virus from being neutralized by the host's natural defenses. Cells infected with Ebolavirus secrete these proteins thereby guiding the humoral response against the limited number of epitopes [12-13]. Produced in abundance, sGP, ssGP and shed GP misdirect the majority of IgG, reducing the efficacy of the host's humoral response [14]. These glycoproteins (especially sGP and ssGP) trigger production of antibodies that have zero or weak virus-neutralizing potential, causing the phenomenon of antibody-dependent enhancement of the infection: the antibodies recognize the virus and interact with Fc-receptors of phagocytes, "ordering" the latter to take up the virus-antibody complexes via FcyR-mediated phagocytosis [15]. Importantly, although secreted forms of GP have binding sites for the protective antibodies, not all animals vaccinated with truncated forms of proteins develop protective immunity against the virus. A strong immune response against EVD can be achieved in all vaccinated animals only when a full-length GP is used [16-18]. This is probably due to the presence of additional neutralization sites and T-cell epitopes in the structure of the full-length protein. This hypothesis is supported by a few observations. Firstly, there are reports that apart from GP1 (glycan cap)-recognizing antibodies isolated from convalescent patients, those that specifically bind to the submembrane domain of GP2 also have protective potential [18-21]. Secondly, a study of CD8+-memory cells in convalescent patients has identified glycoprotein epitopes crucial for provoking a protective T-cell response, among which are regions of the receptor-binding domain and the glycan cap of GP [22].

Table 1. EVD case fatality in patients infected with different ebolaviruses. The table shows summarized data on the total number individuals with EVD in all reported outbreaks [4]

Species Number of Infected Individuals Number of deaths Fatality rate, %

ZEBOV 30154 12503 40-90

SUDV 792 426 36-65

BDBV 206 66 25-51

RESTV 0/13* 0 0

TAFV 1 0 0

BOMV 0 0 0

Note: * — clinical symptoms not observed; antibodies against RESTV detected in the blood serum.

Because a full-fledged protective immune response can be induced by using a full-length glycoprotein or structures expressing the gp gene, the majority of candidate and approved vaccines against ebolaviruses are based on the GP glycoprotein [23-24].

Analysis of cross-reactive immunity in vaccinated individuals and patients recovered from EVD

An ideal EVD vaccine must ensure protection against all variants of Ebolavirus that infect humans. Therefore, it is important to understand whether immune response can be induced against both homologous and phylogenetically distant species. The vaccine based on the recombinant vesicular stomatitis virus (rVSV-ZEBOV) that expresses glycoprotein GP of the ebolavirus isolated in 1995 has been reported to protect non-human primates against infection with any of known ZEBOV strains (isolated in 1976, 1995 and 2014) [25]. Studies of sera samples obtained from patients recovering from ZEBOV confirm those findings: IgG antibodies detected in the sera of the patients were capable of cross-reacting with glycoproteins of heterologous species SUDV and BDBV [26-27]. The studies of cross-

protective immunity in non-human primates demonstrate that the use of ZEBOV glycoprotein (as a component of the rVSV vaccine) confers protection against the lethal BDBV infection in 100% of animals; in contrast, the rVSV-SUDV vaccine does not protect all animals against ZEBOV and BDBV [28-30].

Research into cross-protective immunity against EVD in animals has revealed that postvaccination immunity is cross-protective against ZEBOV and BDBV but not against these species and SUDV.

In search of explanation for this phenomenon, we compared the structure of GP in different species of the ebolavirus. We aligned amino acid sequences of ZEBOV, SUDV and BDBV and mapped immunodominant GP epitopes (i. e., those with the highest immunogenicity; IE) in 1,548 Ebola virus isolates; 10 BDBV, 23 SUDV and 1,515 ZEBOV sequences were taken from a public database [31].

The detailed analysis of immunodominant regions carried out in T Cell Epitope Prediction Tools in the deimmunization mode [32] allowed us to identify 22 IE (Table 2 and 3). The vastest diversity was observed for the mucin domain of GP1; the lowest, for GP2. Paired comparison of IE revealed that homology between ZEBOV and BDBV immunodominant L

VP40

Fig. 1. The structure of Ebolavirus. GP — glycoprotein; L — catalytic subunit of the viral RNA-dependent RNA polymerase; NP — nucleoprotein; VP24 — minor matrix protein; VP30 — minor nucleoprotein; VP35 — nucleocapsid protein; VP40 — matrix protein

Genomic (-) RNA

Leader sequence(

3'-

_ _ _ _ _ _ _ Trailer

■ NP |VP35j-VP40- GP ^VP30-VP24| L

1,

mRNA sGP

I7A)—

No shift (71%)

¥

WÊB^m

sGP precursor

A-peptide--j

■Bill 0

- -

324 5-5 =

mRNA GP

-;8A)_

+1 shift (25%)

501-502

5P

33 22 313 464 ' 599 632 676

«¡1 RBD i GC MLD i§HR. HRJP

1 U J

Precursor of full-length GP

GP1

GP2

502

Secreted sGP dimer

Membrane GP trimer

Shed GP

mRNA

ssGP

_|6/9A|—

-1/+2 shift (4%)

WHO

Precursor of ssGP

n

Secreted ssGP dimer

Fig. 2. Forms of Ebolavirus glycoprotein in eukaryotic cells. GC — glycan cap (glycan cap); HR — heptad repeat; HPR — hydrophobic region; MLD — mucin-like domain (mucin domain); RBD — receptor-binding domain; SP — signal peptide; TD — transmembrane domain

glycoprotein epitopes was 75.8%; between ZEBOV and SUDV, 63.2%; and between SUDV and BDBV, 61.5% (Table 2). It should be noted that glycoproteins representing different of ZEBOV isolates dating back to 1976, 1995, 2014 and 2018 are almost identical and only have minor differences in the region of the glycan cap and the mucin domain (Table 3). On average, IE homology was 98.7-100%.

The obtained data suggest closer phylogenetic relationship between ZEBOV and BDBV, in comparison with SUDV, but do not explain the difference in their ability to induce immune response in animals immunized with the corresponding variants of GP. So, we decided to analyze the sites that bind antibodies conferring cross-protective immunity against the lethal infection caused by various ebolavirus species. Such antibodies are specific to both GP1 and the regions adjacent to the transmembrane domain of GP2 [19-21, 33]. A few recent works point to the fact that protective antibodies bind to the conformational epitopes of GP and not to the linear ones [34-36]. Our analysis of GP sequences has revealed that positions of key amino acids essential for antibody binding are quite conserved. The analysis of sites for binding antibodies with protective potential shows that the positions of key amino acids (i.e., those whose substitution fully blocks the ability of the antibodies to bind to GP) in ZEBOV epitopes are absolutely identical to the positions of amino acids BDBV GP epitopes. Homology between these

amino acids and those found in SUDV glycoprotein varies from 30 to 60% (Fig. 3). In our opinion, mutations at such amino acid positions inhibit the protective potential of the antibodies. It seems that homology of the sites that bind the protective antibodies to the glycoproteins representing different Ebolavirus species is the factor that ensures cross-protective immunity against ZEBOV and BDBV and the lack of cross-protective immune response against these two species and SUDV.

The discovery of universal antibodies capable of protecting humans against pathogenic ebolaviruses [19-21, 33-34, 36] will boost the development of effective EBD therapies and inspire new approaches to the design vaccines against this virus. Studies of cross-protective immunity and antibodies isolated from convalescent patients with EVD give us hope that a ZEBOV GP-based vaccine inducing immunity against both ZEBOV u BDBV is not just wishful thinking. Adding SUDV glycoprotein to the vaccine would make it effective against SUDV species, as well.

CONCLUSIONS

The comparative analysis of GP in 1,548 ZEBOV, SUDV and BDBV isolates has demonstrated a high variability of amino acid sequences in the glycoproteins representing different ebolaviruses (~60-65% homology). Further analysis of epitope

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

Table 2. Homology of amino acid sequences of glycoprotein IE In ZEBOV, SUDV and BDBV viruses. The search for IE was conducted In T Cell Epitope Prediction Tools [32]; amino acid sequences were compared in Geneious® 10.2.3 (Biomatters; Auckland, New Zealand). The heat map shows homology is expressed as %: dark gray stands for 100%, white represents 0%

Amino acid positions Homology of amino acid sequences of GP in ZEBOV, SUDV and BDBV, %

ZEBOV vs SUDV vs BDBV ZEBOV vs SUDV ZEBOV vs BDBV SUDV vs BDBV

93-127* 82.9 91.4 88.6 82.9

151-165 86.7 93.3 93.3 93.3

RBD 156-170 86.7 93.3 93.3 86.7

161-175 73.3 86.7 86.7 73.3

171-185 66.7 80.0 86.7 66.7

190-204** 40.0 53.3 73.3 53.3

211-225 26.7 26.7 40.0 53.3

214-247* 26.5 29.4 58.8 35.3

GP1 d 231-245 40.0 46.7 73.3 40.0

о d 236-250 40.0 46.7 86.7 40.0

та о 241-255 53.3 53.3 86.7 53.3

CD 246-260 66.7 66.7 80.0 66.7

251-265 53.3 53.3 73.3 53.3

271-285** 26.7 40.0 66.7 26.7

389-405** 0.0 17.6 5.9 11.8

о ZD 5 401-417** 5.9 5.9 17.6 17.6

476-490** 33.3 53.3 53.3 40.0

505-519** 66.7 73.3 73.3 66.7

566-580 100 100 100 100

571-585 86.7 86.7 100 86.7

GP2 576-590 86.7 86.7 100 86.7

581-595 80.0 80.0 100 80.0

599-631** 90.9 90.9 97.0 93.9

632-651** 70.0 70.0 90.0 75.0

Average homology (%) 58.0 63.2 75.8 61.5

Note: * — IE essential for inducing protective T-cell-mediated immune response [22]; ** — IE essential for inducing protective B-cell-mediated immune response [20, 34-38].

Table 3. Homology of amino acid sequences of ZEBOV glycoprotein IE (Isolates from 1976, 1995, 2014 and 2018). The search for IE was conducted In T Cell Epitope Prediction Tools [32]; amino acid sequences were compared in Geneious® 10.2.3 (Biomatters; Auckland, New Zealand). The heat map shows homology is expressed as %: dark gray stands for 100%, white represents 0%

Amino acid Homology of amino acid sequences of ZEBOV glycoprotein In the Isolates from 1976, 1995, 2014 and 2018, %

positions 1976-1995-2014-2018 1976-1995 1976-2014 1976-2018 1995-2014 1995-2018 2014-2018

93-127* 100 100 100 100 100 100 100

RBD 151-165 100 100 100 100 100 100 100

156-170 100 100 100 100 100 100 100

161-175 100 100 100 100 100 100 100

171-185 100 100 100 100 100 100 100

190-204** 100 100 100 100 100 100 100

211-225 100 100 100 100 100 100 100

214-247* 100 100 100 100 100 100 100

GP1 231-245 100 100 100 100 100 100 100

ro o c= 236-250 100 100 100 100 100 100 100

a o ^ CD 241-255 100 100 100 100 100 100 100

246-260 100 100 100 100 100 100 100

251-265 93.3 100 93.3 100 93.3 100 93.3

271-285** 100 100 100 100 100 100 100

389-405** 94.1 100 94.1 100 94.1 100 94.1

ö ZD 401-417** 88.2 100 88.2 100 88.2 100 88.2

476-490** 93.3 100 100 93.3 100 93.3 93.3

505-519** 100 100 100 100 100 100 100

566-580 100 100 100 100 100 100 100

GP2 571-585 100 100 100 100 100 100 100

576-590 100 100 100 100 100 100 100

581-595 100 100 100 100 100 100 100

599-631** 100 100 100 100 100 100 100

632-651** 100 100 100 100 100 100 100

Average homology (%) 98.7 100 99.0 99.7 99.0 99.7 98.7

Note: * — IE essential for inducing protective T-cell-mediated immune response [22]; ** — IE essential for inducing protective B-cell-mediated immune response [20, 34-38].

gp1

Antibody 226/8.1 130 a 190 __ 9 ph __ :oo

SUDV l:W« R C R YB ra e th l q1 1 RE IA

BDBV l:W« R CRY! Hi k DU f q1 9 pb l he 1 p

zebov IJtlJJ im ra k db f S E 9mq l RE ip

Antibody 1H3 :7o

sudv am@ri bdbv üuIlkti zebov shbki

tlda k vn p k vnp

gp2

Antibody 2G4

_ 510

sudv K a t 3

bdbv R t q Ûl

zebov na q p

KCNPNLH

Antibody 133/16.3

.550

sudv bdbv zebov

t e g l m h n <

t e g 1 m h n i

t e g l m h n 1

un a|

51N Gl

a Li Gi

IVI 111

Fig. 3. The aligned consensus amino acid sequences of glycoprotein of ZEBOV SUDV and BDBV species. Key amino acid positions essential for antibody binding are marked by a rectangle [34, 36]

homology in the glycoproteins of ZEBOV, SUDV and BDBV, accounting for the tertiary protein structure, has established that ZEBOV and BDBV glycoproteins have identical amino acids capable of binding to the protective antibodies and thus neutralizing these viral species characterized by low homology of linear amino acid sequences. These findings are fully consistent with the reports of the ability of candidate and approved vaccines against Ebolavirus to induce cross-immunity

against ZEBOV and BDBV. Protection against the lethal infection caused by SUDV can be ensured only by vaccines based on SUDV GP.

We believe that the facts listed above clearly establish that development of effective vaccine protecting humans against pathogenic Ebolavirus species should focus on vectors expressing at least two glycoprotein types: of ZEBOV and SUDV.

References

1. Beer B, Kurth R, Bukreyev A. Characteristics of Filoviridae: Marburg and Ebola viruses. Naturwissenschaften. 1999; 86 (1): 8-17.

2. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations. Archives of Virology. 2010; 155 (12): 2083-103.

3. Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravard A, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nature Microbiology. 2018; 3 (10): 1084-89.

4. CDC. Cases and Outbreaks of EVD by Year [updated 2018 Nov 9; cited 2018 Nov 12]. Available from: https://www.cdc.gov/vhf/ ebola/history/chronology.html.

5. Levy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet. 2018; 392 (10149): 787-90.

6. Bharat TA, Noda T, Riches JD, Kraehling V, Kolesnikova L, Becker S, et al. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc Natl Acad Sci USA. 2012; 109 (11): 4275-80.

7. Volchkov VE, Becker S, Volchkova VA, Ternovoj VA, Kotov AN, Netesov SV, et al. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology. 1995; 214 (2): 421-30.

8. Cook JD, Lee JE. The Secret Life of Viral Entry Glycoproteins: Moonlighting in Immune Evasion. PLoS Pathog. 2013; 9 (5): e1003258.

9. He J, Melnik LI, Komin A, Wiedman G, Fuselier T, Morris CF, et al. Ebola Virus Delta Peptide is a Viroporin. J Virol. 2017; 91 (16): e00438-17.

10. Lee JE, Saphire EO. Ebolavirus glycoprotein structure and mechanism of entry. Future virology. 2009; 4 (6): 621-35.

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

11. Wang H, Shi Y, Song J, Qi J, Lu G, Yan J, et al. Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Cell. 2016; 164 (1-2): 258-68.

12. Sanchez A, Yang ZY, Xu L, Nabel GJ, Crews T, Peters CJ. Biochemical Analysis of the Secreted and Virion Glycoproteins of Ebola Virus. J Virol. 1998; 72 (8): 6442-47.

13. Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J, et al. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J. 2004; 23 (10): 2175-84.

14. Ito H, Watanabe S, Takada A, Kawaoka Y. Ebola Virus Glycoprotein: Proteolytic Processing, Acylation, Cell Tropism, and Detection of Neutralizing Antibodies. J Virol. 2001; 75 (3): 1576-80.

15. Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, et al. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Rep. 2018; 24 (7): 1802-15.

16. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006; 3 (6): e177.

17. Li W, Ye L, Carrion R, Nunneley J, Staples H, Ticer A, et al. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice. J Infect Dis. 2015; 212 (Suppl 2): S398-403.

18. Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM,

Wec AZ, et al. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell. 2018; 174 (4): 938-52.

19. Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, et al. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell. 2017; 169 (5): 878-90.

20. Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, et al. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity. 2018; 49 (2): 363-74.

21. Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat Microbiol. 2018; 3 (6): 670-77.

22. Sakabe S, Sullivan BM, Hartnett JN, Robles-Sikisaka R, Gangavarapu K, Cubitt B, et al. Analysis of CD8+ T cell response during the 2013-2016 Ebola epidemic in West Africa. Proc Natl Acad Sci USA. 2018; 115 (32): E7578-E7586.

23. Lévy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet. 2018; 392 (10149): 787-90.

24. Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, Tukhvatulin AI, Shcheblyakov DV, Voronina OL, et al. Virus-Vectored Ebola Vaccines. Acta Naturae. 2017; 9 (3): 4-11.

25. Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015; 349 (6249): 739-42.

26. Macneil A, Reed Z, Rollin PE. Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis. 2011; 5 (6): 1175.

27. Natesan M, Jensen SM, Keasey SL, Kamata T, Kuehne AI, Stonier SW, et al. Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. Clin Vaccine Immunol. 2016; (23): 717-24.

28. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog. 2010; 6 (5): e1000904.

29. Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis. 2013; (7): e2600.

30. Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis. 2011; 204 (Suppl 3): S1066-74.

31. Hatcher EL, Zhdanov SA, Bao Y, Blinkova O, Nawrocki EP, Ostapchuck Y, et al. Virus Variation Resource — improved response to emergent viral outbreaks. Nucleic Acids Res. 2016; 45 (D1): 482-90.

32. T Cell Epitope Prediction Tools [cited 2018 Nov 12]. Available from: http://tools.iedb.org/main/tcell/.

33. Ilinykh PA, Santos RI, Gunn BM, Kuzmina NA, Shen X, Huang K, et al. Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. PLoS Pathog. 2018; 14 (8): e1007204.

34. Audet J, Wong G, Wang H, Lu G, Gao GF, Kobinger G,

et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep. 2014; (4): 6881.

35. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci USA. 2014; 111 (48): 17182-7.

36. Ponomarenko J, Vaughan K, Sette A, Maurer-Stroh S. Conservancy of mAb Epitopes in Ebolavirus Glycoproteins of Previous and 2014 Outbreaks. PLoS Curr. 2014; (6).

37. Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, et al. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell. 2017; 169 (5): 891-904.

38. Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 2016; 351 (6279): 1343-6.

Литература

1. Beer B, Kurth R, Bukreyev A. Characteristics of Filoviridae: Marburg and Ebola viruses. Naturwissenschaften. 1999; 86 (1): 8-17.

2. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations. Archives of Virology. 2010; 155 (12): 2083-103.

3. Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravard A, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nature Microbiology. 2018; 3 (10): 1084-89.

4. CDC. Cases and Outbreaks of EVD by Year [updated 2018 Nov 9; cited 2018 Nov 12]. Available from: https://www.cdc.gov/vhf/ ebola/history/chronology.html.

5. Lévy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet. 2018; 392 (10149): 787-90.